Pfizer’s quest for market share in the ‘high stakes battleground’ of oral GLP-1s

Pfizer’s second-to-market goals for its oral GLP-1 drugs underscore big opportunities in the space.

Pharma takes aim at a wily foe — the Epstein-Barr virus

The pernicious and widespread virus has been linked to a range of diseases including MS and long COVID.

A sickle cell cure exists. But patients need more than just gene therapy.

Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the outlook for patients feels shakier.